Gene:
TDG
thymine-DNA glycosylase

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  G/T mismatch-specific thymine DNA glycosylase
Alternate Symbols:  None
PharmGKB Accession Id: PA36419

Details

Cytogenetic Location: chr12 : q23.3 - q23.3
GP mRNA Boundary: chr12 : 104359593 - 104382656
GP Gene Boundary: chr12 : 104349593 - 104385656
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Fluoropyrimidine Pathway, Pharmacodynamics
    Model non-tissue-specific cancer cell displaying genes which may be involved in the pharmacodynamics of the fluoropyrimidines, 5-fluorouracil (5-FU), capecitabine and tegafur.

External Pathways

Links to non-PharmGKB pathways.

  1. Cleavage of the damaged pyrimidine - (Reactome via Pathway Interaction Database)
  2. Displacement of DNA glycosylase by APE1 - (Reactome via Pathway Interaction Database)
  3. Recognition and association of DNA glycosylase with site containing an affected pyrimidine - (Reactome via Pathway Interaction Database)

Publications related to TDG: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS biology. 2009. Kunz Christophe, et al. PubMed

LinkOuts

Entrez Gene:
6996
OMIM:
601423
UCSC Genome Browser:
NM_003211
RefSeq RNA:
NM_003211
RefSeq Protein:
NP_003202
RefSeq DNA:
AC_000055
AC_000144
NC_000012
NT_029419
NW_001838061
NW_925395
UniProtKB:
B4E127_HUMAN (B4E127)
TDG_HUMAN (Q13569)
Ensembl:
ENSG00000139372
GenAtlas:
TDG
GeneCard:
TDG
MutDB:
TDG
ALFRED:
LO012771S
HuGE:
TDG
Comparative Toxicogenomics Database:
6996
ModBase:
Q13569
HumanCyc Gene:
HS06615
HGNC:
11700

Common Searches